Quadrant Capital Group’s Kite Pharma, Inc. KITE Stock Holding History

Quadrant Capital Group’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-92	Closed	-$5K	–	2146
2016 Q3	$5K	Hold	92	–	–	﹤0.01%	1286
2016 Q2	$4K	Hold	92	–	–	﹤0.01%	1305
2016 Q1	$4K	Buy	+92	New	+$4.46K	﹤0.01%	1251

Other funds holding KITE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Quadrant Capital Group's KITE Position: Q4 2016 in Review

Quadrant Capital Group sold out of Kite Pharma, Inc. (KITE) in Q4 2016, closing a stake of 92 shares — an estimated $5K sold.

Quadrant Capital Group first reported a position in KITE in Q1 2016 and held it in 3 quarters. The position peaked at $5K in Q3 2016. 184 funds tracked by Wall St. Rank hold KITE as of Q4 2016.

Quadrant Capital Group reported no remaining Kite Pharma, Inc. position as of Q4 2016 after selling out during the quarter.
Quadrant Capital Group sold 92 Kite Pharma, Inc. shares in Q4 2016, an estimated $5K.
Quadrant Capital Group first reported a position in Kite Pharma, Inc. in Q1 2016 and held it in 3 quarters.
Quadrant Capital Group's Kite Pharma, Inc. position peaked at $5K in Q3 2016.
184 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2016.

Based on Quadrant Capital Group's 13F filing for Q4 2016, filed 11 Jan 2017.